These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 10646877

  • 1. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
    Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S, Goldstone AH, Linch DC.
    Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877
    [Abstract] [Full Text] [Related]

  • 2. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C.
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [Abstract] [Full Text] [Related]

  • 3. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 4. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou SY, Zhou AP, Zhang CG, Ai B.
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [Abstract] [Full Text] [Related]

  • 5. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
    Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I.
    Bone Marrow Transplant; 2006 Feb; 37(3):277-82. PubMed ID: 16400345
    [Abstract] [Full Text] [Related]

  • 6. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
    Stewart DA, Guo D, Morris D, Poon MC, Ruether BA, Jones AR, Klassen J, Auer I, Luider J, Chaudhry A, Brown C, Russell JA.
    Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
    [Abstract] [Full Text] [Related]

  • 7. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
    Reiser M, Josting A, Draube A, Mapara MY, Scheid C, Chemnitz J, Tesch H, Wolf J, Diehl V, Söhngen D, Engert A.
    Bone Marrow Transplant; 1999 Jun; 23(12):1223-8. PubMed ID: 10414907
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [Abstract] [Full Text] [Related]

  • 9. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma.
    Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A, Crump M.
    Bone Marrow Transplant; 2002 Sep; 30(5):273-8. PubMed ID: 12209348
    [Abstract] [Full Text] [Related]

  • 10. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
    Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V.
    Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G.
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [Abstract] [Full Text] [Related]

  • 12. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Cesana C, Regazzi E, Garau D, Caramatti C, Mangoni L, Rizzoli V.
    Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
    [Abstract] [Full Text] [Related]

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 14. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R, Díaz MA, Granda A, Bernardo MR, Escudero A, López-Lorenzo JL, Fernández-Rañada JM.
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [Abstract] [Full Text] [Related]

  • 15. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
    Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, Jang S, Park CJ, Chi HS, Huh J, Suh C.
    Transfusion; 2007 Aug; 47(8):1447-54. PubMed ID: 17655589
    [Abstract] [Full Text] [Related]

  • 16. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
    Martínez C, Sureda A, Martino R, Cancelas JA, Madoz P, García J, Brunet S.
    Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
    [Abstract] [Full Text] [Related]

  • 17. [Peripheral blood stem cell collection in pediatric malignancies: comparison between three mobilizing regimens].
    De Pasquale MD, Cacchione A, Foco M, Gozzer M, Libera F, Soscia F, Ragni G, Cappelli C.
    Clin Ter; 2003 Nov; 154(5):305-9. PubMed ID: 14994920
    [Abstract] [Full Text] [Related]

  • 18. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
    Kröger N, Zeller W, Hassan HT, Krüger W, Gutensohn K, Löliger C, Zander AR.
    Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
    [Abstract] [Full Text] [Related]

  • 19. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M, Sureda A, Martino R, Madoz P, García J, Brunet S.
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [Abstract] [Full Text] [Related]

  • 20. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.